| abstract |
This invention relates to a method of treating muscle disorders, such as muscular dystrophy, which demonstrate a decrease in muscle protein synthesis, an increase in protein degradation or both. The treatment comprises the administration of an effective dose of insulin-like growth factor I ('IGF-I') or genetically engineered human IGF-I (hIGF-I) to a mammalian subject. The invention also includes a method of IGF-I or hIGF-I treatment combined with a high protein diet and/or exercise regimen to further IGF-I or hIGF-I related improvement. |